Cite
Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.
MLA
van Dijk, Anneke D., et al. “Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.” Cancers, vol. 16, no. 8, Apr. 2024, p. 1448. EBSCOhost, https://doi.org/10.3390/cancers16081448.
APA
van Dijk, A. D., Hoff, F. W., Qiu, Y., Hubner, S. E., Go, R. L., Ruvolo, V. R., Leonti, A. R., Gerbing, R. B., Gamis, A. S., Aplenc, R., Kolb, E. A., Alonzo, T. A., Meshinchi, S., de Bont, E. S. J. M., Horton, T. M., & Kornblau, S. M. (2024). Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial. Cancers, 16(8), 1448. https://doi.org/10.3390/cancers16081448
Chicago
van Dijk, Anneke D., Fieke W. Hoff, Yihua Qiu, Stefan E. Hubner, Robin L. Go, Vivian R. Ruvolo, Amanda R. Leonti, et al. 2024. “Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.” Cancers 16 (8): 1448. doi:10.3390/cancers16081448.